Computational neoantigen prediction for cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Cancer is a major global health issue with significant morbidity and mortality.
• Cancer cells possess tumor-specific antigens (neoantigens) arising from genetic alterations.
• Neoantigens are key targets for personalized cancer vaccines and immunotherapies.

Purpose of the Study:

• To review computational tools and strategies for neoantigen identification and prediction.
• To discuss the integration of multi-omics data for neoantigen validation.
• To explore the clinical application and future prospects of neoantigen-based cancer treatments.

Main Methods:

• Utilizing bioinformatics tools to identify somatic mutations and predict neoantigens based on MHC binding and immunogenicity.
• Employing computational Human Leukocyte Antigen (HLA) haplotyping from sequencing data.
• Integrating immunopeptidomics and proteogenomic strategies for neoantigen validation.

Main Results:

• Computational tools are rapidly advancing, enhancing the accuracy of neoantigen prediction.
• Proteogenomic approaches provide experimental validation by detecting naturally presented peptides.
• Multi-omics integration strengthens confidence in identified neoantigens.

Conclusions:

• Neoantigen identification is essential for developing effective personalized cancer immunotherapies.
• Advancements in bioinformatics and validation techniques are crucial for clinical translation.
• Further research is needed to overcome limitations and optimize neoantigen-based therapeutic strategies.